Point72 Asset Management
LRMR icon

Point72 Asset Management’s Larimar Therapeutics LRMR Stock Holding History

Point72 Asset Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$411K Sell
134,806
-912,579
-87% -$3.62M ﹤0.01% 3259
2026
Q1 		$4.71M Sell
1,047,385
-413,643
-28% -$1.65M 0.01% 1747
2025
Q4 		$5.57M Buy
1,461,028
+237,162
+19% +$922K 0.01% 1768
2025
Q3 		$3.95M Buy
+1,223,866
New +$4.59M 0.01% 1161
2024
Q4 		– Sell
-207,100
Closed -$1.36M – 2286
2024
Q3 		$1.36M Sell
207,100
-396,481
-66% -$3.19M ﹤0.01% 1319
2024
Q2 		$4.38M Buy
603,581
+165,181
+38% +$1.27M 0.01% 872
2024
Q1 		$3.33M Sell
438,400
-12,000
-3% -$93.5K 0.01% 1104
2023
Q4 		$2.05M Sell
450,400
-4,600
-1% -$15.5K 0.01% 1196
2023
Q3 		$1.8M Sell
455,000
-384,000
-46% -$1.45M 0.01% 1163
2023
Q2 		$2.63M Buy
839,000
+384,000
+84% +$1.57M 0.01% 985
2023
Q1 		$2.06M Sell
455,000
-20,000
-4% -$104K 0.01% 970
2022
Q4 		$1.96M Hold
475,000
– – 0.01% 937
2022
Q3 		$1.52M Buy
+475,000
New +$1.19M 0.01% 987
2022
Q1 		– Sell
-196,896
Closed -$2.13M – 1295
2021
Q4 		$2.13M Hold
196,896
– – 0.01% 817
2021
Q3 		$2.27M Buy
196,896
+97,736
+99% +$1.17M 0.01% 776
2021
Q2 		$974K Buy
99,160
+81,900
+475% +$925K ﹤0.01% 818
2021
Q1 		$252K Hold
17,260
– – ﹤0.01% 882
2020
Q4 		$370K Hold
17,260
– – ﹤0.01% 855
2020
Q3 		$262K Hold
17,260
– – ﹤0.01% 858
2020
Q2 		$222K Sell
17,260
-1
-0% -$12 ﹤0.01% 747
2020
Q1 		$159K Hold
17,261
– – ﹤0.01% 723
2019
Q4 		$230K Buy
+17,261
New +$165K ﹤0.01% 834
2019
Q1 		– Sell
-43,678
Closed -$2.59M – 1135
2018
Q4 		$2.59M Buy
43,678
+12,887
+42% +$1.27M 0.01% 677
2018
Q3 		$4.32M Sell
30,791
-10,042
-25% -$1.22M 0.02% 632
2018
Q2 		$5.01M Buy
+40,833
New +$3.47M 0.02% 604
2015
Q2 		– Sell
-217
Closed -$103K – 794
2015
Q1 		$103K Buy
+217
New +$103K ﹤0.01% 662

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Point72 Asset Management's LRMR Position: Q2 2026 in Review

Point72 Asset Management reduced its Larimar Therapeutics (LRMR) stake by 87% in Q2 2026, selling an estimated $3.62M and leaving 134,806 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

Point72 Asset Management first reported a position in LRMR in Q1 2015 and has held it in 26 quarters since. The position peaked at $5.57M in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Point72 Asset Management held 134,806 shares of Larimar Therapeutics worth $411K as of Q2 2026.
  • Point72 Asset Management sold 912,579 Larimar Therapeutics shares in Q2 2026, an estimated $3.62M.
  • Larimar Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3259 holding.
  • Point72 Asset Management first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 26 quarters since.
  • Point72 Asset Management's Larimar Therapeutics position peaked at $5.57M in Q4 2025.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.